Current Research Funding:

NIH RF1 AG078201 “Microglia dysregulation and SYK signaling in Alzheimer’s disease” (2023-2026), PI

NIH RF1 NS130616 “Neurotoxicity of particulate matter and its interaction with APOE in neurodegeneration” (2022-2025), PI

NIH U01 AG074960 “Novel reengineered microbiome-based biologic therapy to treat cognitive and behavioral symptoms of Alzheimer’s disease and related dementias” (2022 – 2027), Co-I

UCI MIND Women’s Alzheimer Movement (WAM) Initiative Grant “Differential vulnerability to air pollution for AD among males and females” (2022 – 2023), PI

NIH R41AG074777 “Evaluation of in vivo efficacy of a novel microbial therapy to treat cognitive deficits in Alzheimer’s disease” (2021 – 2022, NCE 2022 – 2023), Co-I

NIH R43 AG073040 “A humanized organ plate paradigm for high throughput Alzheimer’s disease therapeutics” (2021 – 2022, NCE 2022 – 2023), Co-I

NIH R01AG066806 “Cell-type-specific vulnerability of the entorhinal cortex in Alzheimer’s disease” (2020 – 2025), Co-I

Completed Research Funding:

NIH R21 ES028496 (2018 – 2021) “Mechanism of particulate matter-induced neurotoxicity and cognitive decline in mice”

ADDF Preclinical Research Grant (2017-2020)

NIH R01 ES024331 (2014 – 2020)

University of California, Irvine School of Medicine Faculty Research Grant (2016 – 2017)

NIH K99/R00 (2007 – 2014)

Alzheimer’s Association New Investigator Research Grant (2012 – 2014)

ONO Pharmaceutical contracted grant

University of California, Merced Faculty Research Grant

ARM Research Grant